Cargando…
Classic Psychedelic Drugs: Update on Biological Mechanisms
Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new importa...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110100/ https://www.ncbi.nlm.nih.gov/pubmed/35079988 http://dx.doi.org/10.1055/a-1721-2914 |
_version_ | 1784709026461777920 |
---|---|
author | Vollenweider, Franz X. Smallridge, John W. |
author_facet | Vollenweider, Franz X. Smallridge, John W. |
author_sort | Vollenweider, Franz X. |
collection | PubMed |
description | Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics. |
format | Online Article Text |
id | pubmed-9110100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-91101002022-05-17 Classic Psychedelic Drugs: Update on Biological Mechanisms Vollenweider, Franz X. Smallridge, John W. Pharmacopsychiatry Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics. Georg Thieme Verlag KG 2022-01-25 /pmc/articles/PMC9110100/ /pubmed/35079988 http://dx.doi.org/10.1055/a-1721-2914 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Vollenweider, Franz X. Smallridge, John W. Classic Psychedelic Drugs: Update on Biological Mechanisms |
title | Classic Psychedelic Drugs: Update on Biological
Mechanisms |
title_full | Classic Psychedelic Drugs: Update on Biological
Mechanisms |
title_fullStr | Classic Psychedelic Drugs: Update on Biological
Mechanisms |
title_full_unstemmed | Classic Psychedelic Drugs: Update on Biological
Mechanisms |
title_short | Classic Psychedelic Drugs: Update on Biological
Mechanisms |
title_sort | classic psychedelic drugs: update on biological
mechanisms |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110100/ https://www.ncbi.nlm.nih.gov/pubmed/35079988 http://dx.doi.org/10.1055/a-1721-2914 |
work_keys_str_mv | AT vollenweiderfranzx classicpsychedelicdrugsupdateonbiologicalmechanisms AT smallridgejohnw classicpsychedelicdrugsupdateonbiologicalmechanisms |